305 related articles for article (PubMed ID: 29549631)
1. Combined BRAF
Campennì A; Ruggeri RM; Siracusa M; Pignata SA; Di Mauro F; Vento A; Trimarchi F; Baldari S
J Endocrinol Invest; 2018 Nov; 41(11):1283-1288. PubMed ID: 29549631
[TBL] [Abstract][Full Text] [Related]
2. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
3. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
Li J; Liang J; Zhao T; Lin Y
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
[TBL] [Abstract][Full Text] [Related]
4. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
5. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
[TBL] [Abstract][Full Text] [Related]
6. The correlation of post-operative radioiodine uptake and Tc-99m pertechnetate thyroid scintigraphy and the result of thyroid remnant ablation.
Thientunyakit T; Pusuwan P; Tuchinda P; Khiewvan B
J Med Assoc Thai; 2013 Sep; 96(9):1199-207. PubMed ID: 24163997
[TBL] [Abstract][Full Text] [Related]
7. Clinical usefulness of 99mTc-MIBI scintigraphy in the postsurgical evaluation of patients with differentiated thyroid cancer.
Campennì A; Violi MA; Ruggeri RM; Sindoni A; Moleti M; Vermiglio F; Baldari S
Nucl Med Commun; 2010 Apr; 31(4):274-9. PubMed ID: 20087239
[TBL] [Abstract][Full Text] [Related]
8. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
9.
Giovanella L; Paone G; Ruberto T; Ceriani L; Trimboli P
Endocrinol Metab (Seoul); 2019 Mar; 34(1):63-69. PubMed ID: 30784242
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation.
Dadparvar S; Chevres A; Tulchinsky M; Krishna-Badrinath L; Khan AS; Slizofski WJ
Eur J Nucl Med; 1995 Nov; 22(11):1330-8. PubMed ID: 8575487
[TBL] [Abstract][Full Text] [Related]
11. RADIOISOTOPE DIAGNOSTIC ALGORITHM FOR THE RELAPSE AND METASTASES DETECTION IN THE IODINE-NEGATIVE DIFFERENTIATED THYROID CANCER.
Solodyannikova OI; Kmetyuk YV; Danilenko VV; Sukach GG
Probl Radiac Med Radiobiol; 2020 Dec; 25():579-591. PubMed ID: 33361863
[TBL] [Abstract][Full Text] [Related]
12. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
Rothenberg SM; McFadden DG; Palmer EL; Daniels GH; Wirth LJ
Clin Cancer Res; 2015 Mar; 21(5):1028-35. PubMed ID: 25549723
[TBL] [Abstract][Full Text] [Related]
13. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
14. Clinical approach in patients with metastatic differentiated thyroid carcinoma and negative 131I whole body scintigraphy: importance of 99mTc MIBI scan combined with high resolution neck ultrasonography.
Casara D; Rubello D; Saladini G; Mazzarotto R; Sotti G; Tomasella G; Pelizzo MR
Tumori; 1999; 85(2):122-7. PubMed ID: 10363078
[TBL] [Abstract][Full Text] [Related]
15. Tc-99m MIBI SPECT in detecting metastatic papillary thyroid carcinoma in patients with elevated human serum thyroglobulin levels but negative I-131 whole body scan.
Hsu CH; Liu FY; Yen RF; Kao CH
Endocr Res; 2003 Feb; 29(1):9-15. PubMed ID: 12665314
[TBL] [Abstract][Full Text] [Related]
16. The Value of
Okudan B; Seven B; Gülaldı NCM; Çapraz M; Açıkgöz Y
Curr Med Imaging; 2022; 18(4):404-408. PubMed ID: 34749623
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer.
Grünwald F; Menzel C; Bender H; Palmedo H; Willkomm P; Ruhlmann J; Franckson T; Biersack HJ
Thyroid; 1997 Jun; 7(3):327-35. PubMed ID: 9226199
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcome of Radioiodine Therapy in Low-intermediate Risk Papillary Thyroid Carcinoma with BRAF(V600E) Mutation.
Li J; Yang T; Zhao T; Liang J; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Jun; 38(3):346-50. PubMed ID: 27544995
[TBL] [Abstract][Full Text] [Related]
19. Clinical importance of technetium-99m-methoxyisobutylisonitrile (MIBI) scintigraphy in differentiated thyroid carcinoma patients with elevated thyroglobulin levels and negative I-131 scanning results.
Küçük NO; Külak HA; Aras G
Ann Nucl Med; 2006 Jul; 20(6):393-7. PubMed ID: 16922467
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic capabilities of I-131, TI-201, and Tc-99m-MIBI scintigraphy for metastatic differentiated thyroid carcinoma after total thyroidectomy.
Fujie S; Okumura Y; Sato S; Akaki S; Katsui K; Himei K; Takemoto M; Kanazawa S
Acta Med Okayama; 2005 Jun; 59(3):99-107. PubMed ID: 16049563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
